Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sonja Mariotti Nesurini"'
Autor:
Thomas R. Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J.-Matthias Graf von der Schulenburg, Volker E. Amelung, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from th
Externí odkaz:
https://doaj.org/article/b0233d39cbbf4519bd29290918586e0e
Autor:
Jörg Ruof, Sonja Mariotti Nesurini, Johann-Matthias Graf von der Schulenburg, Charalabos-Markos Dintsios, Volker Amelung, Miriam Walter, T.R. Staab
Publikováno v:
Health Economics Review, Vol 8, Iss 1, Pp 1-11 (2018)
Health Economics Review
Health Economics Review 8 (2018), Nr. 1
Health Economics Review
Health Economics Review 8 (2018), Nr. 1
Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from the market
Autor:
Charalabos-Markos Dintsios, T.R. Staab, Miriam Walter, Christof Iking-Konert, Georg Isbary, Sonja Mariotti Nesurini, Volker Amelung, Jörg Ruof
Publikováno v:
Value in Health. 21:698-706
In oncology clinical trials, crossover is used frequently but may lead to uncertainties regarding treatment effects.To investigate the handling of evidence from crossover trials by the European Medicines Agency (EMA) and the German Federal Joint Comm